Geneva, May 29 -- International Clinical Trials Registry received information related to the study (ChiCTR2600125080) titled 'A single-centre, randomised, double-blind, placebo-controlled, phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HEC-007 injection in healthy subjects administered as a single dose and in overweight or obese subjects administered as multiple doses' on May 21.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: The Second Hospital of Anhui Medical University
Condition:
Overweight, obesity, type 2 diabetes
Intervention:
Group 1 (Part A: SAD):HEC-007 injection 0.1 mg, single abdominal subcutaneous dose on D1 under fasting conditions
all 4...